Few Layer Reduced Graphene Oxide: Evaluation of the Best Experimental Conditions for Easy Production

This work aimed to produce graphene oxide with few graphene layers, a low number of defects, good conductivity and reasonable amount of oxygen, adequate for use as filler in polymeric composites. Two starting materials were evaluated: expanded graphite and graphite flakes. The method of oxidation used was the Staudenmaier one, which was tested over different lengths of time. No appreciable differences were found among the oxidation times and so the lowest oxidation time (24 h) was chosen as the most adequate. An investigation was also conducted into suitable temperatures for the reduction of graphite oxide. A temperature of 1000 ºC gave the best results, allowing a good quality material with few defects to be obtained. The reduction was also evaluated under inert and normal atmosphere. The best results were obtained when the least modified material, e. g., graphite flakes, was used as a starting material, oxidized for 24h and reduced at 1000 ºC for 30 s in a quartz ampoule under a normal atmosphere

Erythropoietic protoporphyria

Erythropoietic protoporphyria (EPP) is an inherited disorder of the haem metabolic pathway characterised by accumulation of protoporphyrin in blood, erythrocytes and tissues, and cutaneous manifestations of photosensitivity. EPP has been reported worldwide, with prevalence between 1:75,000 and 1:200,000. It usually manifests in early infancy upon the first sun exposures. EPP is characterised by cutaneous manifestations of acute painful photosensitivity with erythema and oedema, sometimes with petechiae, together with stinging and burning sensations upon exposure to sunlight, without blisters. These episodes have a variable severity depending on the exposure duration and may result in chronic permanent lesions on exposed skin. As protoporphyrin is a lipophilic molecule that is excreted by the liver, EPP patients are at risk of cholelithiasis with obstructive episodes, and chronic liver disease that might evolve to rapid acute liver failure. In most patients, EPP results from a partial deficiency of the last enzyme of the haem biosynthetic pathway, ferrochelatase, EC 4.99.1.1/FECH (encoded by the FECH gene). EPP appears to be inherited as an autosomal dominant disease, the clinical expression of which is modulated by the presence of the hypomorphic FECH IVS3-48C allele trans, but recessive inheritance with two mutated FECH alleles has also been described. In about 2% of patients, overt disease was recently shown to be caused by gain-of-function mutations in the erythroid-specific aminolevulinic acid synthase 2 (ALAS2/ALAS, EC 2.3.1.27) gene and named X-linked dominant protoporphyria. Diagnosis is established by finding increased levels of protoporphyrin in plasma and red blood cells, and detection of a plasma fluorescence peak at 634 nm. Investigations for hepatic involvement, ferrochelatase activity level, genetic analysis (FECH mutations, presence of the hypomorphic FECH IVS3-48C allele trans and ALAS2 mutations) and family studies are advisable. Differential diagnosis includes phototoxic drug reactions, hydroa vacciniforme, solar urticaria, contact dermatitis, angio-oedema and, in some cases, other types of porphyria. Management includes avoidance of exposure to light, reduction of protoporphyrin levels and prevention of progression of possible liver disease to liver failure. As the major risk in EPP patients is liver disease, a regular follow-up of hepatic involvement is essential. Sequential hepatic and bone marrow transplantation should be considered as a suitable treatment for most severe cases of EPP with hepatic involvement. EPP is a lifelong disorder whose prognosis depends on the evolution of the hepatic disease. However, photosensitivity may have a significant impact on quality of life of EPP patients

Molecular Cloning of a New Immunomodulatory Protein from Anoectochilus formosanus which Induces B Cell IgM Secretion through a T-Independent Mechanism

An immunomodulatory protein (IPAF) was purified and cloned from Anoectochilus formosanus, an Orchidaceae herbal plant in Asia. The major targeting immune cells of IPAF and its modulating effects toward B lymphocytes were investigated. Rapid amplification of cDNA ends (RACE) was conducted to clone the IPAF gene, and the obtained sequence was BLAST compared on the NCBI database. MACS-purified mouse T and B lymphocytes were stimulated with IPAF and the cell proliferation, activation, and Igs production were examined. IPAF comprised a 25 amino acids signal peptide and a 138 amino acids protein which was homologous to the lectins from Orchidaceae plant. IPAF selectively induced the cell proliferation in mouse splenic B lymphocytes but not T lymphocytes. The IPAF-induced B cells exhibited increased CD69 and MHC class II expression, and a dose- and time-dependent enhancement in IgM production. These results suggested potential benefits of IPAF to strengthen the humoral immunity

Graphenes in the absence of metals as carbocatalysts for selective acetylene hydrogenation and alkene hydrogenation

Catalysis makes possible a chemical reaction by increasing the transformation rate. Hydrogenation of carbon-carbon multiple bonds is one of the most important examples of catalytic reactions. Currently, this type of reaction is carried out in petrochemistry at very large scale, using noble metals such as platinum and palladium or first row transition metals such as nickel. Catalysis is dominated by metals and in many cases by precious ones. Here we report that graphene (a single layer of one-atom-thick carbon atoms) can replace metals for hydrogenation of carbon-carbon multiple bonds. Besides alkene hydrogenation, we have shown that graphenes also exhibit high selectivity for the hydrogenation of acetylene in the presence of a large excess of ethylene.This study was financially supported by the Spanish Ministry of Economy and Competitiveness (Severo Ochoa and CTQ2012-32315); and Generalidad Valenciana (Prometeo 21/013) is gratefully acknowledged.Primo Arnau, AM.; Neatu, F.; Florea, M.; Parvulescu, V.; García Gómez, H. (2014). Graphenes in the absence of metals as carbocatalysts for selective acetylene hydrogenation and alkene hydrogenation. Nature Communications. 5:1-9. https://doi.org/10.1038/ncomms6291S195Dreyer, D. R. & Bielawski, C. W. Carbocatalysis: heterogeneous carbons finding utility in synthetic chemistry. Chem. Sci. 2, 1233–1240 (2011).Machado, B. F. & Serp, P. Graphene-based materials for catalysis. Catal. Sci. Technol. 2, 54–75 (2012).Schaetz, A., Zeltner, M. & Stark, W. J. Carbon modifications and surfaces for catalytic organic transformations. ACS Catal. 2, 1267–1284 (2012).Su, D. S. et al. Metal-free heterogeneous catalysis for sustainable chemistry. ChemSusChem 3, 169–180 (2010).Chauhan, S. M. S. & Mishra, S. Use of graphite oxide and graphene oxide as catalysts in the synthesis of dipyrromethane and calix[4]pyrrole. Molecules 16, 7256–7266 (2011).Dreyer, D. R., Jarvis, K. A., Ferreira, P. J. & Bielawski, C. W. Graphite oxide as a carbocatalyst for the preparation of fullerene-reinforced polyester and polyamide nanocomposites. Polym. Chem. 3, 757–766 (2012).Dreyer, D. R., Park, S., Bielawski, C. W. & Ruoff, R. S. The chemistry of graphene oxide. Chem. Soc. Rev. 39, 228–240 (2010).Pyun, J. Graphene oxide as catalyst: application of carbon materials beyond nanotechnology. Angew. Chem. Int. Ed. 50, 46–48 (2011).Rourke, J. P. et al. The real graphene oxide revealed: stripping the oxidative debris from the graphene-like sheets. Angew. Chem. Int. Ed. 50, 3173–3177 (2011).Sun, H. et al. Reduced graphene oxide for catalytic oxidation of aqueous organic pollutants. ACS Appl. Mater. Interf. 4, 5466–5471 (2012).Dreyer, D. R., Jia, H. P. & Bielawski, C. W. Graphene oxide: a convenient carbocatalyst for facilitating oxidation and hydration reactions. Angew. Chem. Int. Ed. 49, 6813–6816 (2010).Dreyer, D. R., Jia, H. P., Todd, A. D., Geng, J. X. & Bielawski, C. W. Graphite oxide: a selective and highly efficient oxidant of thiols and sulfides. Org. Biomol. Chem. 9, 7292–7295 (2011).Hayashi, M. Oxidation using activated carbon and molecular oxygen system. Chem. Rec. 8, 252–267 (2008).Jia, H. P., Dreyer, D. R. & Bielawski, C. W. C-H oxidation using graphite oxide. Tetrahedron 67, 4431–4434 (2011).Kumar, A. V. & Rao, K. R. Recyclable graphite oxide catalyzed Friedel-Crafts addition of indoles to alpha, beta-unsaturated ketones. Tetrahedron Lett. 52, 5188–5191 (2011).Soria-Sanchez, M. et al. Carbon nanostructure materials as direct catalysts for phenol oxidation in aqueous phase. Appl. Catal. B Environ. 104, 101–109 (2011).Verma, S. et al. Graphene oxide: an efficient and reusable carbocatalyst for aza-Michael addition of amines to activated alkenes. Chem. Commun. 47, 12673–12675 (2011).Yu, H. et al. Solvent-free catalytic dehydrative etherification of benzyl alcohol over graphene oxide. Chem. Phys. Lett. 583, 146–150 (2013).Holschumacher, D., Bannenberg, T., Hrib, C. G., Jones, P. G. & Tamm, M. Heterolytic dihydrogen activation by a frustrated carbene-borane Lewis pair. Angew. Chem. Int. Ed. 47, 7428–7432 (2008).Staubitz, A., Robertson, A. P. M., Sloan, M. E. & Manners, I. Amine- and phosphine-borane adducts: new interest in old molecules. Chem. Rev. 110, 4023–4078 (2010).Stephan, D. W. & Erker, G. Frustrated Lewis Pairs: Metal-free Hydrogen Activation and More. Angew. Chem. Int. Ed. 49, 46–76 (2010).Poh, H. L., Sanek, F., Sofer, Z. & Pumera, M. High-pressure hydrogenation of graphene: towards graphane. Nanoscale 4, 7006–7011 (2012).Sofo, J. O., Chaudhari, A. S. & Barber, G. D. Graphane: A two-dimensional hydrocarbon. J. Phys. Chem. B 75, 153401 (2007).Elias, D. C. et al. Control of graphene’s properties by reversible hydrogenation: evidence for graphane. Science 323, 610–613 (2009).Despiau-Pujo, E. et al. Elementary processes of H2 plasma-graphene interaction: a combined molecular dynamics and density functional theory study. J. Appl. Phys. 113, 114302 (2013).Xu, L. & Ge, Q. Effects of defects and dopants in graphene on hydrogen interaction in graphene-supported NaAlH4. Int. J. Hydrogen Energy 38, 3670–3680 (2013).Perhun, T. I., Bychko, I. B., Trypolsky, A. I. & Strizhak, P. E. Catalytic properties of graphene material in the hydrogenation of ethylene. Theor. Exp. Chem. 48, 367–370 (2013).Hummers, W. S. & Offeman, R. E. Preparation of graphitic oxide. J. Am. Chem. Soc. 80, 1339 (1958).Dhakshinamoorthy, A., Primo, A., Concepcion, P., Alvaro, M. & Garcia, H. Doped graphene as a metal-free carbocatalyst for the selective aerobic oxidation of benzylic hydrocarbons, cyclooctane and styrene. Chem. Eur. J. 19, 7547–7554 (2013).Latorre-Sanchez, M., Primo, A. & Garcia, H. P-doped graphene obtained by pyrolysis of modified alginate as a photocatalyst for hydrogen generation from water-methanol mixtures. Angew. Chem. Int. Ed. 52, 11813–11816 (2013).Primo, A., Sanchez, E., Delgado, J. M. & Garcia, H. High-yield production of N-doped graphitic platelets by aqueous exfoliation of pyrolyzed chitosan. Carbon N. Y. 68, 777–783 (2014).Stankovich, S. et al. Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide. Carbon N. Y. 45, 1558–1565 (2007).Pumera, M. & Wong, C. H. A. Graphane and hydrogenated graphene. Chem. Soc. Rev. 42, 5987–5995 (2013).Teschner, D. et al. The roles of subsurface carbon and hydrogen in palladium-catalyzed alkyne hydrogenation. Science 320, 86–89 (2008).Bridier, B., Lopez, N. & Perez-Ramirez, J. Molecular understanding of alkyne hydrogenation for the design of selective catalysts. Dalton Trans. 39, 8412–8419 (2010).Flick, K., Herion, C. & Allmann, H. Palladium-haltiger Trägerkatalysator zur selektiven katalytischen Hydrierung von Acetylen in Kohlenwasserstoffströmen. EP764463-A; EP764463-A2; DE19535402-A1; JP9141097-A; CA2185721-A; KR97014834-A; MX9604031-A1; US5847250-A; US5856262-A; TW388722-A; MX195137-B; CN1151908-A; EP764463-B1; DE59610365-G; ES2197222-T3; KR418161-B; CN1081487-C; JP3939787-B2; CA2185721-C (1997).Gartside, R. J. et al. Improved olefin plant recovery system employing a combination of catalytic distillation and fixed bed catalytic steps. WO2005080530-A1; EP1711581-A1; BR200418414-A; MX2006008045-A1; JP2007518864-W; KR2007005565-A; CN1961059-A; IN200604063-P1; KR825662-B1; JP4376908-B2; CA2553962-C; IN251202-B; SG124072-A1; SG124072-B; CN1961059-B (2005).Wegerer, D. A., Bussche, K. V. & Vandenbussche, K. M. Selective Co oxidation for acetylene converter feed Co CONTROL. US2012294774-A1; US8431094-B2 (2102).Chernichenko, K. et al. A frustrated-Lewis-pair approach to catalytic reduction of alkynes to cis-alkenes. Nat. Chem. 5, 718–723 (2013).Vile, G., Bridier, B., Wichert, J. & Perez-Ramirez, J. Ceria in hydrogenation catalysis: high selectivity in the conversion of alkynes to olefins. Angew. Chem. Int. Ed. 51, 8620–8623 (2012).Ambrosi, A. et al. Metallic impurities in graphenes prepared from graphite can dramatically influence their properties. Angew. Chem. Int. Ed. 51, 500–503 (2012).Ambrosi, A. et al. Chemical reduced graphene contains inherent metallic impurities present in parent natural and synthetic graphite. Proc. Natl Acad. Sci. USA 109, 12899–12904 (2012).Vile, G., Almora-Barrios, N., Mitchell, S., Lopez, N. & Perez-Ramirez, J. From the lindlar catalyst to supported ligand-modified palladium nanoparticles: selectivity patterns and accessibility constraints in the continuous-flow three-phase hydrogenation of acetylenic compounds. Chemistry 20, 5849–5849 (2014).Gurrath, M. et al. Palladium catalysts on activated carbon supports—Influence of reduction temperature, origin of the support and pretreatments of the carbon surface. Carbon N. Y. 38, 1241–1255 (2000).Stephan, D. W. ‘Frustrated Lewis pairs’: a concept for new reactivity and catalysis. Org. Biomol. Chem. 6, 1535–1539 (2008).Stephan, D. W. Frustrated Lewis pairs: a new strategy to small molecule activation and hydrogenation catalysis. Dalton Trans. 17, 3129–3136 (2009).Chase, P. A., Jurca, T. & Stephan, D. W. Lewis acid-catalyzed hydrogenation: B(C6F5)3-mediated reduction of imines and nitriles with H2. Chem. Commun. 14, 1701–1703 (2008).Hounjet, L. J. & Stephan, D. W. Hydrogenation by frustrated Lewis pairs: main group alternatives to transition metal catalysts? Org. Process Res. Dev. 18, 385–391 (2014).Spies, P. et al. Metal-free catalytic hydrogenation of enamines, imines, and conjugated phosphinoalkenylboranes. Angew. Chem. Int. Ed. 47, 7543–7546 (2008).Greb, L. et al. Metal-free catalytic olefin hydrogenation: low-temperature H2 activation by frustrated Lewis pairs. Angew. Chem. Int. Ed. 51, 10164–10168 (2012)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities. This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity. Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55% of the global rise in mean BMI from 1985 to 2017—and more than 80% in some low- and middle-income regions—was due to increases in BMI in rural areas. This large contribution stems from the fact that, with the exception of women in sub-Saharan Africa, BMI is increasing at the same rate or faster in rural areas than in cities in low- and middle-income regions. These trends have in turn resulted in a closing—and in some countries reversal—of the gap in BMI between urban and rural areas in low- and middle-income countries, especially for women. In high-income and industrialized countries, we noted a persistently higher rural BMI, especially for women. There is an urgent need for an integrated approach to rural nutrition that enhances financial and physical access to healthy foods, to avoid replacing the rural undernutrition disadvantage in poor countries with a more general malnutrition disadvantage that entails excessive consumption of low-quality calories

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Measurements of photo-nuclear jet production in Pb plus Pb collisions with ATLAS

Ultra-peripheral heavy ion collisions provide a unique opportunity to study the parton distributions in the colliding nuclei via the measurement of photo-nuclear jet production. An analysis of jet production in ultra-peripheral Pb+Pb collisions at √sNN = 5.02 TeV performed using data collected with the ATLAS detector in 2015 is described. The data set corresponds to a total Pb+Pb integrated luminosity of 0.38 nb−1. The ultra-peripheral collisions are selected using a combination of forward neutron and rapidity gap requirements. The cross-sections, not unfolded for detector response, are compared to results from Pythia Monte Carlo simulations re-weighted to match a photon spectrum obtained from the STARlight model. Qualitative agreement between data and these simulations is observed over a broad kinematic range suggesting that using these collisions to measure nuclear parton distributions is experimentally realisable